Clinical trials
Phase 4 Diabetes Mellitus trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Unknown status | 6 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Health Network, Toronto | 6 |
| Eli Lilly and Company | 4 |
| Novo Nordisk A/S | 4 |
| Hamilton Health Sciences Corporation | 3 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 2 |
| GlaxoSmithKline | 2 |
| LMC Diabetes & Endocrinology Ltd. | 2 |
| Population Health Research Institute | 2 |
| Unity Health Toronto | 2 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 41 |
| Diabetes Mellitus, Type 2 | 25 |
| Diabetes Mellitus, Type 1 | 7 |
| Insulin Resistance | 7 |
| Cardiovascular Diseases | 4 |
| Hyperlipidemias | 3 |
| Hypertension | 2 |
| Acute Coronary Syndrome | 1 |
| Angina Pectoris | 1 |
| Angina, Unstable | 1 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.